Patents Examined by Timothy R Rozof
  • Patent number: 10730845
    Abstract: An ethylene bis-12-hydroxystearamide grafted glycidyl citrate (EBH-g-ECA) and a preparation method thereof are provided; the EBH-g-ECA can be used as a multifunctional auxiliary agent in a polymer material, and particularly has a chain extension and a crystal nucleation effect in a polyester polymer material. A heat-resistant polylactic acid continuously-extruded foamed material containing EBH-g-ECA is further provided. The continuous foaming technology can be realized by using the heat-resistant polylactic acid foamed material, and the prepared foamed product has a high heat resistance, a uniform appearance, a low density, and complete biodegradation. A polylactic acid foamed material preparation method for a heat-resistant is provided, which is easy to be industrialized and has a great significance for realizing the large-scale replacement of petroleum-based plastic disposable foamed products such as PP and PS.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: August 4, 2020
    Inventors: Xiong Wang, Peng Li, Huxiao Chen, Dan Lu
  • Patent number: 10723723
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1 is (II) or (III); each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3, L1, L2, R1a, R1b, R1c, and n are define herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: July 28, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Prashantha Gunaga, Rajeev S. Bhide, Rajesh Onkardas Bora, Manoranjan Panda, Navnath Dnyanoba Yadav, Eldon Scott Priestley, Jeremy Richter
  • Patent number: 10717730
    Abstract: Compositions containing the compound of general formula I: are disclosed. The compositions be used to prevent or treat hepatitis B virus infection.
    Type: Grant
    Filed: March 11, 2020
    Date of Patent: July 21, 2020
    Inventors: Cheng Peng, Yang Zhou, Gang Zou, Danbin Li, Haiqing Yuan, Zhen Jim Wu, Xiashi Lv, Xiaogang Lai, Shaoyun Zhang
  • Patent number: 10717748
    Abstract: The present invention provides a compound useful as an agent for the prophylaxis or treatment of neurodegenerative disease and the like, or a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Grant
    Filed: February 3, 2020
    Date of Patent: July 21, 2020
    Inventors: Tatsuki Koike, Masato Yoshikawa, Haruhi Ando, William John Farnaby
  • Patent number: 10710969
    Abstract: This invention relates to a process for preparing (±)-2-exo-(2-Methylbenzyloxy)-1-methyl-4-isopropyl-7-oxabicyclo[2.2.1]heptane of the formula (I) any of its individual enantiomers or any non-racemic mixture thereof, comprising the steps of (a) reacting (±)-2-exo-hydroxy-1-methyl-4-isopropyl-7-oxabicyclo[2.2.1]heptane of the formula (II) any of its individual enantiomers or any non-racemic mixture thereof with a 2-Methylbenzyl compound of the formula (III) wherein X is a leaving group in the presence of at least one base capable of forming water or a C1-C4 alkyl alcohol under the reaction conditions, and at least one inert organic solvent, and (b) simultaneously removing water, the C1-C4 alkyl alcohol or any mixture thereof from the reaction mixture.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: July 14, 2020
    Assignee: BASF AGRO B.V.
    Inventors: Stefan Benson, Michael Rack, Bernd Wolf, Roland Goetz, Joachim Gebhardt, Helmut Kraus
  • Patent number: 10710971
    Abstract: A method for synthesizing a dicarboxylate containing an aromatic heterocycle is provided. A carboxylic acid containing a heterocycle is provided. A CO32? salt is provided to form a mixture, which converts the carboxylic acid containing an aromatic heterocycle to a carboxylate containing an aromatic heterocycle. CO2 gas is provided to the mixture. The mixture is heated to a temperature to at least partially melt the carboxylate containing an aromatic heterocycle.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: July 14, 2020
    Assignee: The Board of the Trustees of the Leland Stanford Junior University
    Inventors: Matthew W. Kanan, Aanindeeta Banerjee
  • Patent number: 10709692
    Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: July 14, 2020
    Assignee: Denali Therapeutics Inc.
    Inventors: Giorgio Bonanomi, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Colin Philip Leslie, Joseph P. Lyssikatos, Carmela Napolitano, Alfonso Pozzan, Anantha Sudhakar, Zachary K. Sweeney, Federica Tonelli, Javier de Vicente Fidalgo
  • Patent number: 10707019
    Abstract: An electro-polarizable compound has the following general formula: where Core1 is an aromatic polycyclic conjugated molecule having two-dimensional flat form and self-assembling by pi-pi stacking in a column-like supramolecule, which is tetrapirolic macro-cyclic fragment, R1 is an dopant group connected to Core1, m is number of R1 which is equal to 1, 2, 3 or 4, R2 is a substituent comprising one or more ionic groups, p is number of R2 which is equal to 0, 1, 2, 3 or 4. The fragment marked NLE containing the Core1 with at least one R1 has a nonlinear effect of polarization. Core2 is an electro-conductive oligomer self-assembling by pi-pi stacking in a column-like supramolecule, n is number of Core2 which is equal to 2, or 4, R3 is a substituent comprising one or more ionic groups, s is number of R3 which is equal to 0, 1, 2, 3 or 4. R4 is a non-polar resistive substituent, k is a number of R4 which is equal to 0, 1, 2, 3, 4, 5, 6, 7 or 8.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: July 7, 2020
    Inventors: Pavel Ivan Lazarev, Paul T. Furuta, Barry K. Sharp, Yan Li
  • Patent number: 10703750
    Abstract: The present disclosure generally relates to crystalline valbenazine. The present disclosure also generally relates to a pharmaceutical composition comprising crystalline valbenazine, as well of methods of using crystalline valbenazine in the treatment of hyperkinetic disorders, and methods for obtaining such forms.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: July 7, 2020
    Assignee: Sandoz AG
    Inventors: Christoph Langes, Stefan Reissmann
  • Patent number: 10696685
    Abstract: The invention is among others concerned with novel polyketides, their method of production, purification and use. The method can entail providing a bacterium that synthesizes the compound.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: June 30, 2020
    Assignee: Universiteit Leiden
    Inventors: Changsheng Wu, Young-Hae Choi, Gilles Philippus van Wezel
  • Patent number: 10689380
    Abstract: Disclosed herein are new crystalline forms of valbenazine ditosylate designated Form D and Form E, which are characterized using one or more analytical methods, such as X-ray Powder Diffraction analysis. Further disclosed herein are crystalline Form D valbenazine ditosylate in the form of a dichloromethane solvate, and crystalline Form E valbenazine ditosylate in the form of a hydrate. Also disclosed are pharmaceutical compositions comprising these new crystalline forms, and methods of using those compositions for the treatment of various disease states and conditions, including hyperkinetic disorder, such as drug-induced tardive dyskinesia and Tourette's syndrome.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: June 23, 2020
    Assignee: Farmhispania S.A.
    Inventors: Rafel Prohens López, Raquel Cordobilla Cascales, Xavier Pujol Ollé, Óscar Martínez Pérez
  • Patent number: 10689370
    Abstract: The present invention relates to new cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator proteins, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: June 23, 2020
    Inventors: Chengzhi Zhang, Justin Chakma
  • Patent number: 10676427
    Abstract: The present invention relates compounds useful as reagents for the diazomethylation reaction, their preparation and the use thereof as reagents in a method for the diazomethylation reaction of aromatic substrates. It relates in particular to a compound of formula (I) wherein E is an electron withdrawing group.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: June 9, 2020
    Inventors: Marcos García Suero, Zhaofeng Wang
  • Patent number: 10669237
    Abstract: Provided herein is a process for the preparation of 4-((6-bromopyridin-3-yl)oxy)benzonitrile.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: June 2, 2020
    Assignee: Dow AgroSciences LLC
    Inventors: Nicholas R. Babij, Qiang Yang, Kaitlyn Gray, Yan Hao
  • Patent number: 10662207
    Abstract: The present disclosure is directed to disclosed compounds that modulate e.g., address underlying defects in cellular processing of CFTR activity.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: May 26, 2020
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Benito Munoz, Daniel Parks, Cecilia M. Bastos
  • Patent number: 10662167
    Abstract: The invention relates to a method for producing 5-hydroxymethylfurfural (HMF) in a continuous process, which leads to the obtainment of an HMF fraction, a carbohydrate/acid fraction, a fructose fraction, and a levulinic-acid and formic-acid fraction and advantageously makes it possible, because of the purity of the obtained fractions, to return the fructose fraction obtained by means of the method directly to the production process and to use the other fractions in further-processing processes without the need for complex, additional purification steps.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: May 26, 2020
    Assignee: SUDZUCKER AG
    Inventors: Markwart Kunz, Alireza Haji Begli, Christine Kröner, Wolfgang Wach, Alain-Michel Graf, Wolfgang Kraus
  • Patent number: 10654829
    Abstract: Crystalline Forms of Compound I: and pharmaceutically acceptable salts thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: May 19, 2020
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Varsha Dhamankar, Kirk Raymond Dinehart, Eleni Dokou, Lori Ann Ferris, Nishanth Gopinathan, Katie McCarty, Catherine Metzler, Beili Zhang, Samuel Moskowitz, Sarah Robertson, David Waltz, Eric L. Haseltine, Weichao George Chen
  • Patent number: 10654804
    Abstract: Disclosed are compounds of Formula 1, N-oxides of the compounds and salts of the compounds and N-oxides: wherein R1, R2, R3, R4, R5, R6, Q1, Q2, J, Y1, and Y2 are as defined in the disclosure. Also disclosed are compositions containing the compounds, N-oxides and salts, and methods for controlling undesired vegetation comprising contacting the undesired vegetation or its environment with an effective amount of such a compound, N-oxide, salt or composition.
    Type: Grant
    Filed: June 1, 2016
    Date of Patent: May 19, 2020
    Assignee: FMC Corporation
    Inventors: Andrew Duncan Satterfield, Matthew James Campbell, James Francis Bereznak, William Guy Whittingham, Glynn Mitchell, Christopher John Mathews, James Nicholas Scutt, James Alan Morris, Jonathan Wesley Paul Dallimore, Katharine Mary Ingram, Timothy Robert Desson, Kenneth Ling
  • Patent number: 10654821
    Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: R1: e.g., a C1-C6 alkyl group; R2: a C1-C6 alkyl group; A: e.g., an oxygen atom; and R3: e.g., a C1-C6 alkyl group.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: May 19, 2020
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Keiji Saito, Katsuyoshi Nakajima, Toru Taniguchi, Osamu Iwamoto, Satoshi Shibuya, Yasuyuki Ogawa, Kazumasa Aoki, Nobuya Kurikawa, Shinji Tanaka, Momoko Ogitani, Eriko Kioi, Kaori Ito, Natsumi Nishihama, Tsuyoshi Mikkaichi, Wataru Saitoh
  • Patent number: 10654815
    Abstract: The present invention relates to a urea compound and a preparation method and an application thereof. The structure of the present compound is represented by formula (I), the definition of each variable in the formula being as described in the description. The compound can block interaction between the PD-1/PD-L1 signalling pathways. The compound of the present invention can be used for treating or preventing diseases related to the signalling pathways, such as cancer, autoimmune disease, chronic infectious disease, and other diseases.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: May 19, 2020
    Inventors: Qianjiao Yang, Xianping Lu, Zhibin Li, Lijun Xin, Yonglian Song, Chao Fu